NR3C1 and COVID-19: Corticosteroid therapy aims to support the regulatory function of the activated glucocorticoid receptor α; in subjects with severe COVID-19, glucocorticoid receptor expression in bronchoalveolar lavage myeloid cells is negatively related to lung neutrophilic inflammation and severity of symptoms [29].